This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignees: Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet), Fundacion Sales, Inis Biotech LLC. Active years: 2018.
Company Filing History:
1 out of 81 
1 out of 8 
1 out of 20 
Years Active: 2018
Title: Dario Ariel Estrin: Innovator in Immuno-Modulating Polypeptides
Introduction
Dario Ariel Estrin is a notable inventor based in Buenos Aires, Argentina. He has made significant contributions to the field of immunology through his innovative research and patents. His work focuses on the development of Galectin-1 polypeptide variants that possess unique immuno-modulating properties.
Latest Patents
Dario Ariel Estrin holds a patent for "GAL-1 variants having immuno-modulating properties and methods of using the same." This patent describes Galectin-1 polypeptide variants that include a mutation of the histidine residue at position 52 of the full-length amino acid sequence of native human Gal-1. The mutation involves substituting histidine with either tyrosine or asparagine, which provides resistance to acidosis that would otherwise deactivate native human Gal-1. Additionally, these variants may include further mutations of the cysteine residue at positions 2, 16, or 88, with substitutions to serine, enhancing resistance to oxidation.
Career Highlights
Throughout his career, Dario has worked with esteemed organizations such as the National Scientific and Technical Research Council (CONICET) and Fundación Sales. His research has been pivotal in advancing the understanding of immuno-modulating agents and their applications in medical science.
Collaborations
Dario has collaborated with prominent researchers in his field, including Gabriel Adrián Rabinovich and Santiago Di Lella. These partnerships have fostered a collaborative environment that enhances the impact of their research.
Conclusion
Dario Ariel Estrin's innovative work in the development of Galectin-1 polypeptide variants showcases his commitment to advancing immunology. His contributions through patents and collaborations highlight the importance of research in creating new therapeutic options.